- Congressional Research Service Studies Legalizing Marijuana January 25, 2015
- Meshugga – Glass Ice Bong January 24, 2015
- Study Shows Marijuana Helps Relieve Depression January 23, 2015
Marijuana News in Arizona and World
The Congressional Research Service (CRS) released a comprehensive report that examined the establishing of a wholesale excise tax on the production and sale of marijuana-related products on a federal level.
This comprehensive policy and fiscal report of how marijuana can be taxed and regulated nationally included enforcement concerns, discouraging youth use, choosing the base to tax (such as weight, potency, and price), restrictions, labeling, special tax rates, home production and medical marijuana.
CRS’s economic analysis indicated that marijuana prices would likely fall from current-day prohibition-influenced prices of approximately $200-$300 per ounce to potentially less than $20 per ounce. The economic modeling was based on a $40 billion annual US marijuana market that tested a $50 per ounce federal excise tax price point which would generate nearly $7 billion in federal excise tax.
Alcohol and marijuana’s external costs (i.e. taxation to equate with external costs of the drug use on society) were studied and researchers pegged alcohol’s external costs to the nation at $30 billion annually and marijuana’s at less than $1.6 billion, revealing that the federal government understands that alcohol is a much more harmful substance to society than marijuana.
NORML Executive Director commented on the CRS report:
“This CRS report on the prospects of the federal government taxing and regulating cannabis is another clear indication of the political saliency and fiscal appeal of ending cannabis prohibition at the state, and increasingly at the federal level (replacing the nearly eighty-year old failed federal policy with tax-n-regulate policies that are similar to alcohol and tobacco products). With four states and the District of Columbia since 2012 opting for legalizing cannabis, dozens of members of Congress from both major political parties—from states with legalization and those that pine for it—are getting serious about making sure the federal government does not lose out on hundreds of millions annually in tax revenue from the ever-growing cannabis industry in the United States.”
Researchers from The Netherlands published a study in the European Neuropsychology journal that focused on the effects ofon humans while processing emotional content. They found that THC decreased brain activity when faced with negative stimuli.
The researchers used functional magnetic resonance imaging (fMRI) technology to gauge the study subjects’ brain activity. Subjects were shown faces expressing different emotions and then asked whether the person was happy or fearful. This gauged whether THC would effect how the subjects perceived others’ emotions.
Their findings were quite interesting, to say the least: THC decreased brain activity in response to the negative stimuli, but not for the positive stimuli. One researcher stated that “These results indicate that THC administration reduces the negative bias in emotional processing.”
The “negative bias” refers to when a person gives more weight to negative experiences than positive experiences. For example, it’s common for people to be afraid of all dogs after being attacked by a dog. This fear remains embedded in the subconscious despite the many positive experiences a person has had with a dog(s). This reveals to us that negative emotions may be stronger and have more of an impact on someones long-term psyche than positive emotions.
When a negative bias is prevelant in a person’s everyday interactions, it has been linked to depression. Depressed patients often have this negative bias which causes them to perceivein more of a negative way than people without depression. This leads to the notion that THC could be very useful in naturally treating depression and PTSD.
During the 2013 and 2014 fiscal years investments in the legal US marijuana industry (medical and recreational) hit nearly $105 million.
A financial insights company recorded that there were 60 major investment deals involving marijuana-related companies. The largest deal was $75 million raised by a private equity firm based in Seattle. Next was a $20 million investment deal with a company that owns cultivation sites in the Midwest, then $12.4 million in funding for a company that was granted a license to grow and distribute marijuana in Minnesota.
An up-and-coming marijuana industry stock is Northsight Capital, Inc. (OTCBB: NCAP) which owns and operates multiple online marijuana industry business and is based out of Arizona. Two of their biggest sites include 420careers.com, a leading marijuana industry job board, and WeedDepot.com, a new marijuana directory for legal , doctors, head/vape shops, and more. Northsight Capital, Inc. also owns and is developing other marijuana-related sites, all of which will work together to form a vast platform.
It has been predicted that the legal US marijuana industry will expand to over a $10 billion industry by 2018. With recent recreational marijuanapassing in multiple states, and other states expected to follow next year, the industry will likely exceed $10 billion by 2018.
There are currently over 63,000 medical marijuana patients in Arizona, and a new report by the Arizona Department of Health Services (ADHS) revealed that more than 10 tons of marijuana was purchased atover the last year.
That statistics averages out to the equivalent of oneper patient per day. But, as with any medication, some patients consume less than others.
If we estimate the price for an ounce of marijuana from aat $350, that means Arizonans spent about $112 million on medical marijuana over the last year. Furthermore, the ADHS charges $150 per year per medical marijuana card issued, which means the state made over $9 million last year from issuing cards.
The recent Arizona Department of Health Services report also found:
– 85 medical marijuana dispensaries were operating last year.
– Over two-thirds of medical marijuana patients are male.
– The average medical marijuana patient made 17 transactions at dispensaries during the last year.
– Fridays and Saturdays are the two busiest days of the week for dispensaries.
These statistics reveal that Arizona’s medical marijuana industry is steadily growing.
If marijuana gets legalized in Arizona for recreational use in 2016, marijuana sales would likely increase to upwards of $400 million per year.
An Arizonais hosting a giveaway of two (2) tickets to the “big game” in Glendale, Arizona on February 1st.
Urban Greenhouse dispensary contracted a reputable giveaway and sweepstakes company to manage and keep the giveaway fair and legitimate.
The giveaway is completely free and there are multiple ways to enter: online, via mail, or with any purchase at or patient referral to Urban Greenhouse dispensary. Enter to win before January 26th.
Click here to enter to win: Big Game Giveaway
A bill has been filed in the United States Senate (with bi-partisan support) that could legalize industrialcultivation and production throughout the country.
The Industrial Hemp Farming Act of 2015 bill would remove any federal restrictions on the domestic cultivation of industrial hemp. The bill would also remove hemp from being a Schedule I controlled substance and would define it as a non-drug, as long as it contains less than 0.3 percent tetrahydrocannabinol ().
“The U.S. ban on hemp farming is an outrageous restriction on free enterprise and does nothing but hurt economic growth and job creation,” stated Sen. Wyden. “Our bipartisan, common-sense bill is pro-environment, pro-business, and pro-farmer. Congress must act to empower farmers and boost economic activity across the country. As I’ve always said, if you can buy it in Oregon, you should be able to grow it in Oregon.”
Hemp products, such as food and clothing, are legal to sell in the United States, but must be grown in other countries and imported into the United States.
Farmers worldwide grow hemp for commercial purposes, such as for fiber, seed, and oil, which are used in a variety of industrial and consumer products. The United States is the only developed nation that does not cultivate industrial hemp as an economic crop, according to the Congressional Resource Service.
More than thirty countries worldwide produce industrial hemp, including: Australia, Austria, Canada, Chile, China, Denmark, England, Egypt, Finland, France, Germany, Hungary, India, Italy, Japan, Korea, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Slovenia, Spain, Sweden, Switzerland, Thailand, Turkey, Ukraine, among others.
When it comes to consuming marijuana there are many methods of consumption available. Along with rolling a, there is a wide selection of pipes and bongs available on the market. Recently, , tinctures and have become the latest and greatest method for consuming marijuana. This article discusses why vaporizers are the ideal device when consuming marijuana via inhalation.
Vaporizers are prevalent in many countries; for example, in Isreal, vaporizers can be found in hospitals and senior homes. As well, the well-known Volcano Vaporizer is actually an approved medical device in Canada and the EU.
Here are some reasons why vaporizers have become so popular among medical professionals and patients:
Smoking marijuana has not been proven to cause lung cancer, but the combustion of marijuana can still produce toxins that can irritate the lungs. Vaporizers were mainly designed to overcome this problem. Vaporizers heat marijuana at a lower temperature than combustion. They produce an inhalable vapor that still contains the active and beneficial marijuana ingredients (), but without the harmful by-products that combustion creates.
A study conducted in California found that vaporizers convert around 46% of availablein marijuana into vapor; whereas the average joint converted less than 25% of the marijuana’s THC.
When it comes to using lungs to consume marijuana, it appears that vaporizers are the ideal method.
The Arizona Department of Health Services (ADHS) will be accepting petitions for additional debilitating medical conditions to be added to the list of current qualifying medical conditions for medical marijuana use in Arizona from January 26-30, 2015.
This year, on Jan 1, 2015, the ADHS officially made PTSD a qualifying condition for medical marijuana in Arizona. PTSD was petitioned to the ADHS multiple times and finally approved after new research studies found that marijuana can help people with PTSD.
To suggest a new medical marijuana qualifying condition, click here: ADHS
An internal medicine study performed by UPenn researchers found a startlingly clear correlation between states with implemented medical marijuanaand the lowering of opioid death rates. Simply put, states that allow medical marijuana had a 24.8% lower mean annual opioid overdose mortality rate than states that don’t have medical marijuana available as a medicine.
“Approximately 60 percent of all deaths resulting from opioid analgesic overdoses occur in patients who have legitimate prescriptions,” stated Dr. Bachhuber. Moreover, it’s clearly evident that states that offer medical marijuana have a lower rate of opioid deaths and see a favorable decrease in opioid deaths over time.
The statistics show that: year 1 (-19.9%; 95% CI, -30.6% to -7.7%; P?=?.002), year 2 (-25.2%; 95% CI, -40.6% to -5.9%; P?=?.01), year 3 (-23.6%; 95% CI, -41.1% to -1.0%; P?=?.04), year 4 (-20.2%; 95% CI, -33.6% to -4.0%; P?=?.02), year 5 (-33.7%; 95% CI, -50.9% to -10.4%; P?=?.008), and year 6 (-33.3%; 95% CI, -44.7% to -19.6%; P?<?.001).
This study clearly shows that mortality death rates decrease and continue to decrease over time in states with medical marijuana.
Tetrahydrocannabinol () and cannabidiol ( ) are the two most commonly known chemicals that are naturally found in marijuana. Both CBD and THC belong to a unique class of compounds known as .
Marijuana is typically know for its THC content, which provides the psychoactive active aspects or “high” from consuming marijuana. But CBD has begun to draw attention from the medical community because of the amazing health benefits it provides.
THC is best known for being psychoactive. CBD, however, is non-psychoactive. In other words, CBD can’t get you “high” like THC. This lack of a “high,” or lack of side effect as medical professionals like to put it, is one reason why CBD is so appealing as a medicine.
THC is known to help reduce pain, but CBD is the substance that has the most anti-inflammatory properties, making it an all-star at pain reduction and healing. THC and CBD are also know to suppress muscle spams and reduce nausea, making them perfect for chemo patients.
THC is known to cause anxiousness or paranoia in some people, but CBD actually reduces anxiety and can actually counteract the anxiety caused by consuming THC. Studies also suggest that CBD can reduce anxiety when administered on its own.
In addition to being non-psychoactive, CBD also has antipsychotic properties. Researchers believe that CBD might protect marijuana users from getting “too high” by reducing the psychosis-like effects caused by THC. CBD is also being tested as an antipsychotic medicine for patients with schizophrenia.
One of the more common uses of marijuana is as a sleep aid. THC is known to be responsible for most of marijuana’s sleep-inducing effects. On the other hand, studies have suggested that CBD acts to promote wakefulness, making CBD a better choice for daytime use.